These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19859929)

  • 1. Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide.
    Fyfe PK; Rao VA; Zemla A; Cameron S; Hunter WN
    Angew Chem Int Ed Engl; 2009; 48(48):9176-9. PubMed ID: 19859929
    [No Abstract]   [Full Text] [Related]  

  • 2. Metallochaperones Are Needed for Mycobacterium tuberculosis and Escherichia coli Nicotinamidase-Pyrazinamidase Activity.
    Sheen P; Monsalve A; Campos J; Huerta R; Antiparra R; Arteaga H; Duran P; Bueno C; Kirwan DE; Gilman RH; Zimic M
    J Bacteriol; 2020 Jan; 202(2):. PubMed ID: 31636108
    [No Abstract]   [Full Text] [Related]  

  • 3. Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide.
    Petrella S; Gelus-Ziental N; Maudry A; Laurans C; Boudjelloul R; Sougakoff W
    PLoS One; 2011 Jan; 6(1):e15785. PubMed ID: 21283666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility.
    Vats C; Dhanjal J; Goyal S; Gupta A; Bharadvaja N; Grover A
    BMC Genomics; 2015; 16 Suppl 2(Suppl 2):S14. PubMed ID: 25708048
    [No Abstract]   [Full Text] [Related]  

  • 5. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide.
    Sun Z; Zhang Y
    Antimicrob Agents Chemother; 1999 Mar; 43(3):537-42. PubMed ID: 10049264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazinamide.
    Tuberculosis (Edinb); 2008 Mar; 88(2):141-4. PubMed ID: 18486055
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological and Molecular Mechanisms Behind the Sterilizing Activity of Pyrazinamide.
    Gopal P; Grüber G; Dartois V; Dick T
    Trends Pharmacol Sci; 2019 Dec; 40(12):930-940. PubMed ID: 31704175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactive dirty fragments: implications for tuberculosis drug discovery.
    Gopal P; Dick T
    Curr Opin Microbiol; 2014 Oct; 21():7-12. PubMed ID: 25078318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escherichia coli genes involved in resistance to pyrazinoic acid, the active component of the tuberculosis drug pyrazinamide.
    Schaller A; Guo M; Gisanrin O; Zhang Y
    FEMS Microbiol Lett; 2002 Jun; 211(2):265-70. PubMed ID: 12076823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and inhibition of nicotinamidase from Mycobacterium tuberculosis.
    Seiner DR; Hegde SS; Blanchard JS
    Biochemistry; 2010 Nov; 49(44):9613-9. PubMed ID: 20879713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of pyrazinamide derivatives for anti-Mycobacterium tuberculosis.
    Zhou S; Yang S; Huang G
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):1183-1186. PubMed ID: 28870094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-scale computational study on the mechanism of Streptococcus pneumoniae Nicotinamidase (SpNic).
    Ion BF; Kazim E; Gauld JW
    Molecules; 2014 Sep; 19(10):15735-53. PubMed ID: 25268724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides.
    Boshoff HI; Mizrahi V
    J Bacteriol; 2000 Oct; 182(19):5479-85. PubMed ID: 10986252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the host environment on the antitubercular action of pyrazinamide.
    Lamont EA; Baughn AD
    EBioMedicine; 2019 Nov; 49():374-380. PubMed ID: 31669220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular basis of pyrazinamide activity on Mycobacterium tuberculosis PanD.
    Sun Q; Li X; Perez LM; Shi W; Zhang Y; Sacchettini JC
    Nat Commun; 2020 Jan; 11(1):339. PubMed ID: 31953389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA.
    Lemaitre N; Sougakoff W; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1761-3. PubMed ID: 10390238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
    Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
    Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B; Momin MAM; Eedara BB; Sinha S; Das SC
    Int J Pharm; 2019 Oct; 570():118689. PubMed ID: 31513868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.
    Simões MF; Valente E; Gómez MJ; Anes E; Constantino L
    Eur J Pharm Sci; 2009 Jun; 37(3-4):257-63. PubMed ID: 19491013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance mechanism of PncA in Mycobacterium tuberculosis.
    Rajendran V; Sethumadhavan R
    J Biomol Struct Dyn; 2014; 32(2):209-21. PubMed ID: 23383724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.